or Try an Advanced Search...

    Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.36 -3.70% -0.01
    CTXR closed down 3.7 percent on Friday, November 1, 2024, on 61 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CTXR trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish -3.70%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -11.32%
    Crossed Above 20 DMA Bullish -11.32%
    Up 3 Days in a Row Strength -11.32%
    Up 4 Days in a Row Strength -11.32%
    20 DMA Resistance Bearish -8.07%
    Wide Bands Range Expansion -8.07%
    Up 3 Days in a Row Strength -8.07%
    NR7 Range Contraction -2.97%
    Narrow Range Bar Range Contraction -2.97%
    Older End-of-Day Signals for CTXR ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance 1 day ago
    Down 5% 1 day ago
    Down 3% 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Down 2 % 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CTXR Chart by TradingView
    Basic chart:

    Profile

    Citius Pharmaceuticals, Inc. Description

    Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Pharmaceutical Drugs Inflammation Catheter Antibiotics Cancer Care Care Products Prescription Product Prescription Products Acetamides Bloodstream Infections Lidocaine

    Is CTXR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 5 Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    Sep 5 Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
    Aug 13 Sidoti Events, LLC's Virtual August Micro-Cap Conference
    Aug 13 Citius merges oncology subsidiary with TenX Keane
    Aug 13 Citius Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01
    Aug 12 Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
    Aug 12 Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
    Aug 12 Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
    Aug 9 TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
    Aug 8 Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
    See more CTXR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.07
    52 Week Low 0.33
    Average Volume 884,559
    200-Day Moving Average 0.67
    50-Day Moving Average 0.47
    20-Day Moving Average 0.38
    10-Day Moving Average 0.37
    Average True Range 0.04
    RSI (14) 37.11
    ADX 23.04
    +DI 18.40
    -DI 23.87
    Chandelier Exit (Long, 3 ATRs) 0.36
    Chandelier Exit (Short, 3 ATRs) 0.44
    Upper Bollinger Bands 0.42
    Lower Bollinger Band 0.34
    Percent B (%b) 0.22
    BandWidth 19.78
    MACD Line -0.03
    MACD Signal Line -0.04
    MACD Histogram 0.0066
    Fundamentals Value
    Market Cap 57.05 Million
    Num Shares 159 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -1.63
    Price-to-Sales 0.00
    Price-to-Book 1.16
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.40
    Resistance 3 (R3) 0.40 0.39 0.39
    Resistance 2 (R2) 0.39 0.38 0.39 0.39
    Resistance 1 (R1) 0.37 0.37 0.37 0.37 0.39
    Pivot Point 0.36 0.36 0.36 0.36 0.36
    Support 1 (S1) 0.35 0.35 0.34 0.35 0.33
    Support 2 (S2) 0.34 0.35 0.34 0.33
    Support 3 (S3) 0.32 0.34 0.33
    Support 4 (S4) 0.32